A clinical study to evaluate the effects of some Ayurvedic formulations in the management of High blood pressure.

Clinical trial of Parthadyarishta (Arjunarishta) and Sarpagandha Vati in the management of Essential Hypertension (Uccha Raktachap)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/03/005634

Enrollment

Registered

2015-03-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Essential Hypertension

Interventions

Intervention1: PARTHADYARISHTHA(ARJUNARISHTA) along with SARPAGANDHA VATI: PARTHADYARISHTHA(ARJUNARISHTA)- Dose of 20 ml twice daily

Dosage form- Arishta (fermented liquid)

Route of Administration-Oral

Time of Administration-Twice a day after food

Anupana-Water (in equal quantity i.e. 20 ml)

Packing form- A combi pack with one bottle containing 450 ml and one bottle containing 150ml along with a measuring cap. Duration of therapy-12 weeks. SARPAGANDHA VATI- Dose of 500 mg(1 tablets) twice

Dosage form-Tablet of 500 mg

Anupana-Water

Packing form-15gm (30 Tablets of 500 mg)

Duration of therapy-12 weeks. Intervention2: PARTHADYARISHTHA(ARJUNARISHTA)along with SARPAGANDHA VATI.: PARTHADYARISHTHA(ARJUNARISHTA)- Dose of 20 ml twice daily

Packing form- A combi pack with one bottle containing 450 ml and one bottle containing 150ml along with a measuring cap. Duration of therapy-12 weeks. SARPAGANDHA VATI- Dose of 500 mg(1tablets) twice

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed patients of essential hypertension S.B.P. >= 140 Hg. and_ = 90 Hg. and _ 2. Willing and able to participate for 14 weeks

Exclusion criteria

Exclusion criteria: 1. Known clinical diagnosed cases of coronary diseases 2. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 3. Symptomatic patients with clinical evidence of Heart failure. 4. Secondary hypertension. 5 Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT >3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2mg/dl, uncontrolled Pulmonary Dysfunction(asthmatic and COPD patients) or other concurrent severe disease. 6.Patients with Diabetes Mellitus {B.S. (F) > 126 mg/dl and / or B.S. (2 hr. PP) >200 mg/dl} 7. Women who are pregnant or lactating. 8. Patients on steroids, oral contraceptive pills or estrogen replacement therapy. 9. Alcoholics and/or drug abusers. 10.Serum Triglycerides >= 250 mg/dl 11.Patients with evidence of malignancy 12. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.) 13. H/o hypersensitivity to any of the trial drugs or their ingredients. 14. Patients who have completed participation in any other clinical trial during the past six (06) months. 15. Any other condition which the Investigator thinks may jeopardize the study.

Design outcomes

Primary

Measure	Time frame
Changes from baseline measurements in mean sitting systolic blood pressure and mean sitting diastolic blood pressure. Timepoint: At baseline, 14, 28, 42,56,70,84 and at the end of follow up after 14 weeks.	—

Secondary

Measure	Time frame
1. Change in the SF-36-Health Survey Score. 2.Change in Hamilton Anxiety Rating Scale (HAM â?? A) Score Timepoint: 1. At baseline, 84 and at the end of follow up after 14 weeks. 2. At baseline, 14, 28, 42,56,70,84 days and at the end of follow up after 14 weeks.	—

Countries

India

Contacts

Public ContactDr K K Singh

Ayurveda Regional Research Institute, Patna

kks_pat@yahoo.co.in9431039291

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026